Equity Agreement With LLC Gives MediciNova Potential To Move Two Lead Programs Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
A $20 million common stock purchase agreement with Aspire Capital provides MediciNova some breathing room as it attempts to negotiate partnerships around a pair of mid-stage small-molecule candidates.